REVN 24
Alternative Names: REVN-24Latest Information Update: 06 Mar 2024
At a glance
- Originator Chugai Pharmaceutical
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 26 Oct 2023 Phase-I clinical trials in Unspecified (In volunteers) in Japan (IV) (jRCT2071230074), (Roche pipeline, February 2024)